Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Coronavirus / COVID-19 Pandemic -- Ignore unavailable to you. Want to Upgrade?

To: Wharf Rat who wrote (22816)	8/25/2025 2:53:50 PM
From: Sam	Respond to of 22882

Trump administration could ban COVID-19 jabs 'within months': Daily Beast Aug. 25, 2025 11:57 AM ET The Trump administration is reportedly preparing to withdraw the COVID-19 vaccines from the U.S. market within the coming months, according to a new report by the Daily Beast. The report cited Dr. Aseem Malhotra, a close associate to HHS Secretary Robert F. Kennedy Jr., known for his vocal opposition to the vaccines. He informed the Daily Beast that numerous individuals close to RFK Jr. have expressed their confusion regarding the ongoing prescription of the vaccine, and that a decision to withdraw the vaccine from the U.S. market pending additional research is expected to occur “within months,” despite the potential to incite “fear of chaos” and lead to significant legal consequences. “It could [happen] in a number of stages, including learning more about the data,” said Malhotra in the report, who added that there was an ongoing review into “vaccine injuries” by the Advisory Committee on Immunization Practices (ACIP). “But given the increased talk of vaccine injuries in the past few weeks among the administration, it could also come with one clean decision.” This prediction comes after Kennedy’s decision to block $500M in federal funding originally allocated to the development of mRNA-based vaccines. In the report, Malhotra stated that doubts regarding COVID-19 vaccines stem from a peer-reviewed study that analyzed secondary data on “serious adverse events reported in clinical trials of Pfizer and Moderna mRNA COVID-19 vaccines in adults”. The study indicated that individuals who received the mRNA vaccines faced a 16 percent greater risk of experiencing “excess serious adverse events” compared to those in the placebo group. Shares of Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) moved lower on the news. seekingalpha.com